Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
6Customers
2Debt Items
0Related Chains
Source-Backed Evidence Depth
Evolus, Inc. (EOLS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
1Distinct source URLs
7High confidence
0.775Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Evolus, Inc. Suppliers
Ticker
Name
Confidence
Evidence
ALPHAEON-CORPORATION
ALPHAEON-CORPORATION
90%
The Company was acquired by Strathspey Crown Holdings Group, LLC in 2013 and subsequently by its subsidiary, Alphaeon Corporation ("Alphaeon"), by means of a stock purchase agreement ("Stock Purchase…
DAEWOONG-PHARMACEUTICAL-CO-LTD
DAEWOONG-PHARMACEUTICAL-CO-LTD
90%
The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau ® .
STRATHSPEY-CROWN-HOLDINGS-GROUP-LLC
STRATHSPEY-CROWN-HOLDINGS-GROUP-LLC
90%
The Company was acquired by Strathspey Crown Holdings Group, LLC in 2013 and subsequently by its subsidiary, Alphaeon Corporation ("Alphaeon"), by means of a stock purchase agreement ("Stock Purchase…
Evolus, Inc. Customers
Ticker
Name
Confidence
Evidence
MEDYTOX-INC
MEDYTOX-INC
80%
In February 2021, the Company settled the certain litigation with Medytox, Inc. (‘Medytox”) related to Jeuveau ® by means of settlement and license agreements (the "Medytox Settlement Agreements").
BIOPHARMA-CREDIT-PLC
BIOPHARMA-CREDIT-PLC
62%
ncremental borrowings. Total proceeds of $ 23,390 were received by the Company, net of discounts and fees paid to Pharmakon, from the funding of the initial tranche. The second and third tranches, ea…
BPCR-LIMITED
BPCR-LIMITED
62%
ncremental borrowings. Total proceeds of $ 23,390 were received by the Company, net of discounts and fees paid to Pharmakon, from the funding of the initial tranche. The second and third tranches, ea…
DAEWOONG-PHARMACEUTICAL-CO-LTD
DAEWOONG-PHARMACEUTICAL-CO-LTD
62%
Item 1A. “Risk Factors” occurs, our business could be materially and adversely affected. As more fully described in Item 1A. “Risk Factors,” the principal risks and uncertainties that may affect our …
ECLIPSE-BUSINESS-CAPITAL-LLC
ECLIPSE-BUSINESS-CAPITAL-LLC
62%
uveau ® . Net revenues in the three months ended March 31, 2026 and 2025 each contained $0.4 million of service revenue from sales of Jeuveau ® through a distribution partner in Canada. We anticipate…
STRATHSPEY-CROWN-HOLDINGS-GROUP-LLC
STRATHSPEY-CROWN-HOLDINGS-GROUP-LLC
62%
”) approval for the remaining three injectable HA gel products. As a result, the two milestone payments have been triggered. The first milestone payment is payable in October 2026, the two-year anniv…
Evolus, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
EOLS-DEBT-9324
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
EOLS-DEBT
Debt stack $156.7M
90%
Market cache reports total debt of $156.7M.
Evolus, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Evolus, Inc..
Evolus, Inc. Ownership
Holder
Name
Confidence
Evidence
EOLS-OWNER-NANTAHALA-CAPITAL-MANAGEMENT-LLC
Nantahala Capital Management, LLC
90%
13F overlay lists Nantahala Capital Management, LLC as top holder; 149 tracked holders.
Evolus, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
